Concepedia

ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer

Tetsuya Fujii, Shinichi Toyooka, Kouichi Ichimura, Yoshiro Fujiwara, Katsuyuki Hotta, Junichi Soh, Hiroshi Suehisa, Naruyuki Kobayashi, Motoi Aoe, Tadashi Yoshino,

Lung Cancer · 2007 · 80 citations · 24 references

DOI

Concepts

References

24

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Martin M. Oken, Richard H. Creech, Douglass C. Tormey et al. · American Journal of Clinical Oncology · 1982 · 11.6K citations

, , +8

Cancer Statistics, 2006

Ahmedin Jemal, Rebecca L. Siegel, Elizabeth M. Ward et al. · CA A Cancer Journal for Clinicians · 2006 · 5.3K citations · Full text

, , +16

DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy

Ken A. Olaussen, Ariane Dunant, Pierre Fouret et al. · New England Journal of Medicine · 2006 · 1.7K citations · Full text

, , +16

Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.

Reginald V. Lord, Jan Brabender, David R. Gandara et al. · PubMed · 2002 · 671 citations

, , +14

ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.

R. Metzger, Cynthia G. Leichman, Kathleen D. Danenberg et al. · Journal of Clinical Oncology · 1998 · 510 citations

, , +10